IMMUSE is backed by 27 studies, including 12 clinical trials comprised of 10 efficacy studies and two safety studies. It stimulates the body’s natural defenses by activating plasmacytoid dendritic cells (pDCs). These pDCs activate other immune cells, such as NK, killer-T, helper-T, and B cells, that play crucial roles in regular immune function.*